Advertisement
JOGC

Optimal Timing and Aspirin Dose for the Prevention of Preeclampsia

Published:August 02, 2022DOI:https://doi.org/10.1016/j.jogc.2022.07.004
      Preeclampsia affects approximately 5% of pregnant women and is associated with serious perinatal morbidity and mortality. Left untreated, and in its most serious forms, preeclampsia leads to maternal vital organ damage, seizures, long-term cardiovascular diseases, and potentially maternal death. Most of these adverse outcomes are associated with maternal vascular malperfusion of the placenta, a disease that begins during the first trimester when uteroplacental blood flow to the implantation site is increasing exponentially. Because aspirin initiated in the first trimester of pregnancy has been shown to improve placental perfusion and prevent preeclampsia, it is increasingly used in various at-risk populations. However, care must be taken to respect the scientific evidence regarding its optimal use.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roberge S.
        • Bujold E.
        • Nicolaides K.H.
        Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.
        Am J Obstet Gynecol. 2018; 218: 287-293.e1
        • Masotti G.
        • Galanti G.
        • Poggesi L.
        • et al.
        Differential inhibition of prostacyclin production and platelet aggregation by aspirin.
        Lancet. 1979; 2: 1213-1217
        • Rolnik D.L.
        • Wright D.
        • Poon L.C.
        • et al.
        Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia.
        N Engl J Med. 2017; 377: 613-622
        • Kasraeian M.
        • Asadi N.
        • Homeira V.
        • et al.
        The effect of 150 and 80 mg doses of aspirin on preventing preterm birth in high-risk pregnant women.
        J Perinat Med. 2022; https://doi.org/10.1515/jpm-2021-0668
        • Kumar N.
        • Das V.
        • Agarwal A.
        • et al.
        Pilot interventional study comparing fetomaternal outcomes of 150 mg versus 75 mg aspirin starting between 11 and 14 weeks of pregnancy in patients with high risk of preeclampsia: A Randomized Control Trial.
        J Obstet Gynaecol India. 2020; 70: 23-29
        • Tapp S.
        • Guerby P.
        • Girard M.
        • et al.
        A Pilot Randomized Trial comparing the effects of 80 versus 160 mg of aspirin on midtrimester uterine artery pulsatility index in women with a history of preeclampsia.
        J Obstet Gynecol Can. 2020; 42: 1498-1504